- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939594
An Evaluation of the Potential for VH4011499 Drug-drug-interactions
A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: US GSK Clinical Trials Call Center
- Numéro de téléphone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Sauvegarde des contacts de l'étude
- Nom: EU GSK Clinical Trials Call Center
- Numéro de téléphone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).
-
Male or female:
-
Male Participants:
No restrictions for male participants.
-
A female participant (female sex assigned at birth) is eligible to participate if:
-
They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Capable of giving signed informed consent.
Exclusion Criteria:
- History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
- A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
- Clinically significant abnormal blood pressure at Screening.
- Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
- Breast cancer within the past 10 years.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
- History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
- History of seizure(s) and / or other clinically significant neurological conditions.
- Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
- Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
- Participant is mentally or legally incapacitated.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
- Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
- Unable to refrain from the use of prescription or non-prescription medications.
- Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
- Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
- Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
- Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
- Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
- Current enrollment or past participation in this clinical study.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
- Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
- Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
- Positive Hepatitis C antibody test result at Screening.
- Positive pre-study drug/alcohol screen.
- Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
- Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
- Regular alcohol consumption within 6 months prior to Screening.
- Regular use of known drugs of abuse.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
- Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
- Prior exposure to VH4011499 or Lenacapavir in any formulation..
- Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
- Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort 1: VH4011499 + Ritonavir
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir. |
VH4011499 is administered to the participants based on the protocol schedule. Ritonavir is administered to the participants based on the protocol schedule. |
|
Expérimental: Cohort 2: VH4011499 + Efavirenz
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz. |
VH4011499 is administered to the participants based on the protocol schedule. Efavirenz is administered to the participants based on the protocol schedule. |
|
Expérimental: Cohort 3: VH4011499 + Carbamazepine
Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose. |
VH4011499 is administered to the participants based on the protocol schedule. Carbamazepine is administered to the participants based on the protocol schedule. |
|
Expérimental: Cohort 4: VH4011499 + Metformin + Digoxin
Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Metformin is administered to the participants based on the protocol schedule. Digoxin is administered to the participants based on the protocol schedule. |
|
Expérimental: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin
Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499. |
VH4011499 is administered to the participants based on the protocol schedule. Rosuvastatin is administered to the participants based on the protocol schedule. Pitavastatin is administered to the participants based on the protocol schedule. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
Cmax of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
Cmax of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
Cmax of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-t) of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
AUC(0-t) of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
Cmax of Metformin when administered alone
Délai: Day 1
|
Day 1
|
|
Cmax of Metformin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
AUC(0-t) of Metformin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-t) of Metformin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
AUC(0-inf) of Metformin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-inf) of Metformin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
Cmax of Digoxin when administered alone
Délai: Day 1
|
Day 1
|
|
Cmax of Digoxin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
AUC(0-t) of Digoxin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-t) of Digoxin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
AUC(0-inf) of Digoxin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-inf) of Digoxin when co-administered with VH4011499
Délai: Day 16
|
Day 16
|
|
Cmax of Rosuvastatin when administered alone
Délai: Day 5
|
Day 5
|
|
Cmax of Rosuvastatin when co-administered with VH4011499
Délai: Day 22
|
Day 22
|
|
AUC(0-t) of Rosuvastatin when administered alone
Délai: Day 5
|
Day 5
|
|
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
Délai: Day 22
|
Day 22
|
|
AUC(0-inf) of Rosuvastatin when administered alone
Délai: Day 5
|
Day 5
|
|
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
Délai: Day 22
|
Day 22
|
|
Cmax of Pitavastatin when administered alone
Délai: Day 1
|
Day 1
|
|
Cmax of Pitavastatin when co-administered with VH4011499
Délai: Day 17
|
Day 17
|
|
AUC(0-t) of Pitavastatin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-t) of Pitavastatin when co-administered with VH4011499
Délai: Day 17
|
Day 17
|
|
AUC(0-inf) of Pitavastatin when administered alone
Délai: Day 1
|
Day 1
|
|
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
Délai: Day 17
|
Day 17
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with adverse events (AEs), overall and by grade.
Délai: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Number of participants with AEs leading to study treatment discontinuation
Délai: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Délai: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
|
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
Délai: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death. |
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
|
|
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
Tmax of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
|
Tmax of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
|
Tmax of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
|
Apparent oral clearance (CL/F) of VH4011499 when administered alone
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
CL/F of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
|
CL/F of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
|
CL/F of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
|
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
Délai: Day 1 for Cohorts 1, 2 and 3
|
Day 1 for Cohorts 1, 2 and 3
|
|
|
t1/2 of VH4011499 when co-administered with Ritonavir
Délai: Day 26
|
Day 26
|
|
|
t1/2 of VH4011499 when co-administered with Efavirenz
Délai: Day 37
|
Day 37
|
|
|
t1/2 of VH4011499 when co-administered with Carbamazepine
Délai: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Metformin and Digoxin
Délai: Day 16
|
Day 16
|
|
|
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
Délai: Day 16
|
Day 16
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
Délai: Day 16
|
Day 16
|
|
|
Cmax of Ritonavir when co-administered with VH4011499
Délai: Day 26
|
Day 26
|
|
|
AUC(0-t) of Ritonavir when co-administered with VH4011499
Délai: Day 26
|
Day 26
|
|
|
AUC(0-inf) of Ritonavir when co-administered with VH4011499
Délai: Day 26
|
Day 26
|
|
|
Cmax of Efavirenz when co-administered with VH4011499
Délai: Day 37
|
Day 37
|
|
|
AUC(0-t) of Efavirenz when co-administered with VH4011499
Délai: Day 37
|
Day 37
|
|
|
AUC(0-inf) of Efavirenz when co-administered with VH4011499
Délai: Day 37
|
Day 37
|
|
|
Cmax of Carbamazepine when co-administered with VH4011499
Délai: Day 41
|
Day 41
|
|
|
AUC(0-t) of Carbamazepine when co-administered with VH4011499
Délai: Day 41
|
Day 41
|
|
|
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
Délai: Day 41
|
Day 41
|
|
|
Cmax of VH4011499 when co-administered with Rosuvastatin
Délai: Day 22
|
Day 22
|
|
|
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
Délai: Day 22
|
Day 22
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
Délai: Day 22
|
Day 22
|
|
|
Cmax of VH4011499 when co-administered with Pitavastatin
Délai: Day 17
|
Day 17
|
|
|
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
Délai: Day 17
|
Day 17
|
|
|
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
Délai: Day 17
|
Day 17
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections transmissibles par le sang
- Maladies urogénitales
- Maladies génitales
- Maladies du système immunitaire
- Infections
- Infections par virus à ARN
- Maladies virales
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies à virus lents
- Infections à VIH
- Syndrome immunodéficitaire acquis
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, anneau fusionné
- Thiazoles
- Azoles
- Hydrocarbures
- Glucides
- Composés polycycliques
- Glycosides
- Amides
- Pyrimidines
- Stéroïdes
- Composés à anneau fusionné
- Hydrocarbures, halogénés
- Biguanides
- Guanidines
- Amidines
- Sulfonamides
- Sulfones
- Dibenzazépines
- Composés hétérocycliques, 3 ring
- Fluorobenzènes
- Hydrocarbures, fluorés
- Digitalis Glycosides
- Cardenolides
- Glycosides cardiaques
- Cardanolides
- Rosuvastatine calcique
- Digoxine
- Metformine
- Ritonavir
- Carbamazépine
- efavirenz
- pitavastatine
Autres numéros d'identification d'étude
- 309014
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf
Délai de partage IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Critères d'accès au partage IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .